29 results
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
unless terminated by us and/or Evotec. Evotec is currently our sole supplier for mavorixafor drug substance. We are in the process of transitioning … product candidates. Any significant disruption in our supplier relationships could harm our business. We currently rely on a single source supplier
8-K
EX-10.1
XFOR
X4 Pharmaceuticals Inc
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company’s
8-K
EX-10.1
lvk19eexju
1 Jul 22
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
4:34pm
8-K
EX-10.1
k756lab
3 Mar 22
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-10.1
irej augj
5 Nov 21
Entry into a Material Definitive Agreement
5:27pm
8-K
EX-10.1
fqd2q4m8
19 Mar 21
X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing
9:05am